Literature DB >> 22111858

Pharmacokinetic-pharmacodynamic modeling in acute and chronic pain: an overview of the recent literature.

Christian Martini1, Erik Olofsen, Ashraf Yassen, Leon Aarts, Albert Dahan.   

Abstract

In acute and chronic pain, the objective of pharmacokinetic-pharmacodynamic (PKPD) modeling is the development and application of mathematical models to describe and/or predict the time course of the pharmacokinetics (PK) and pharmacodynamics (PD) of analgesic agents and link PK to PD. Performing population PKPD modeling using nonlinear mixed effects modeling allows, apart from the estimation of fixed effects (the PK and PD model estimates), the quantification of random effects as within- and between-subject variability. Effect-compartment models and mechanism-based biophase distribution models that incorporate drug-association and -dissociation kinetics are applied in PKPD modeling of pain treatment. Mechanism-based models enable the quantification of the rate-limiting factors in drug effect owing to drug distribution versus receptor kinetics (since receptor kinetics are nonlinear they are discernable from the linear effect-compartment kinetics). It is a helpful technique in understanding the complex behavior of specific analgesics, such as buprenorphine, but also morphine and its active metabolite morphine-6-glucuronide, especially with respect to the reversal of opioid-induced side effects, most importantly life-threatening respiratory depression. One approach in chronic pain studies is the application of mixture models. Mixture models do not necessarily need to take PK data into account and allow the objective differentiation of measured responses to analgesics into specific response subgroups, and as such, may play an important role in analyzing Phase I and II analgesia studies. Appropriate application of PKPD modeling leads to the improvement of current therapeutics with respect to dose design and outcome, understanding the interaction of analgesics within complex chronic pain disease processes and may play an important role in drug development. In the current article, novel observations using the aforementioned techniques on opioids, NSAIDs, epidural analgesia, ketamine and GABA-ergic drugs in acute and chronic pain are discussed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22111858     DOI: 10.1586/ecp.11.59

Source DB:  PubMed          Journal:  Expert Rev Clin Pharmacol        ISSN: 1751-2433            Impact factor:   5.045


  11 in total

1.  The use of a battery of pain models to detect analgesic properties of compounds: a two-part four-way crossover study.

Authors:  Pieter Okkerse; Guido van Amerongen; Marieke L de Kam; Jasper Stevens; Richard P Butt; Rachel Gurrell; Albert Dahan; Joop M van Gerven; Justin L Hay; Geert Jan Groeneveld
Journal:  Br J Clin Pharmacol       Date:  2017-01-09       Impact factor: 4.335

Review 2.  Deconstructing biomarkers for chronic pain: context- and hypothesis-dependent biomarker types in relation to chronic pain.

Authors:  Diane Reckziegel; Etienne Vachon-Presseau; Bogdan Petre; Thomas J Schnitzer; Marwan N Baliki; A Vania Apkarian
Journal:  Pain       Date:  2019-05       Impact factor: 6.961

3.  Semi-mechanistic modelling of the analgesic effect of gabapentin in the formalin-induced rat model of experimental pain.

Authors:  A Taneja; I F Troconiz; M Danhof; O Della Pasqua
Journal:  Pharm Res       Date:  2013-10-05       Impact factor: 4.200

4.  Pharmacodynamic Analysis of Morphine Time-to-Remedication Events in Infants and Young Children After Congenital Heart Surgery.

Authors:  Mohammed H Elkomy; David R Drover; Jeffery L Galinkin; Gregory B Hammer; Kristi L Glotzbach
Journal:  Clin Pharmacokinet       Date:  2016-10       Impact factor: 6.447

5.  Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery.

Authors:  Justin L Hay; Pieter Okkerse; Guido van Amerongen; Geert Jan Groeneveld
Journal:  J Vis Exp       Date:  2016-04-14       Impact factor: 1.355

6.  Pharmacokinetics and Pharmacodynamics Evaluation of Tramadol in Thermoreversible Gels.

Authors:  Juliana Zampoli Boava Papini; Cíntia Maria Saia Cereda; José Pedrazzoli Júnior; Silvana Aparecida Calafatti; Daniele Ribeiro de Araújo; Giovana Radomille Tofoli
Journal:  Biomed Res Int       Date:  2017-07-27       Impact factor: 3.411

7.  The effects of opioids on HIV reactivation in latently-infected T-lymphoblasts.

Authors:  Johannes Prottengeier; Eleni Koutsilieri; Carsten Scheller
Journal:  AIDS Res Ther       Date:  2014-07-02       Impact factor: 2.250

8.  Influence of Morbid Obesity on the Pharmacokinetics of Morphine, Morphine-3-Glucuronide, and Morphine-6-Glucuronide.

Authors:  Sjoerd de Hoogd; Pyry A J Välitalo; Albert Dahan; Simone van Kralingen; Michael M W Coughtrie; Eric P A van Dongen; Bert van Ramshorst; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2017-12       Impact factor: 6.447

Review 9.  Challenges in translational drug research in neuropathic and inflammatory pain: the prerequisites for a new paradigm.

Authors:  A Taneja; O Della Pasqua; M Danhof
Journal:  Eur J Clin Pharmacol       Date:  2017-09-11       Impact factor: 2.953

10.  Population Pharmacokinetic/Pharmacodynamic Analysis of Nociceptive Pain Models Following an Oral Pregabalin Dose Administration to Healthy Subjects.

Authors:  Michiel J van Esdonk; Ian Lindeman; Pieter Okkerse; Marieke L de Kam; Geert J Groeneveld; Jasper Stevens
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2018-08-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.